Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Teleconference Memorandum - July 8, 2009



Teleconference Memorandum


DATE: July 8, 2009
TIME:   1:35 pm, eastern standard time
SUBJECT:Hiberix BLA STN 125347—Request for clarification regarding Section 6.1 of Hiberix package insert sent by Email 7/8/09
PRODUCT: Hiberix
SPONSOR:GlaxoSmithKline (GSK)
CBER Participants:Karen Farizo
GSK Participants:Elisa Harkins


CBER initiated this call to request clarification regarding Lines 93 and 94 of the Hiberix draft annotated package insert sent by GSK via Email on 7/8/09, as follows:  

In the package insert, GSK indicated that the number of subjects in Hiberix booster immunization studies who were primed with ActHIB was 234 and the number of subjects who were primed with PedvaxHIB was 27. CBER acknowledges that these numbers are consistent with Table 11 in the Summary of Clinical Safety (m2.7.4). However, CBER noted that for Study DTPa-HBV-IPV-035, the data in Table 11 of the Summary of Clinical Safety appear to be inconsistent with the data in Supplement 5 of the Modified Interim Report for Study DTPa-HBV-IPV-035 and in Table 2 of Addendum 1 to the study report. In the latter two tables, it appears that 26 subjects were primed with PedvaxHIB and 40 subjects were primed with ActHIB + Infanrix + Orimune.  

The GSK representative indicated that she would direct this question to one of GSK’s clinical representatives and would provide a response by Email tomorrow.

Call concluded.  

Page Last Updated: 03/23/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English